---
title: "Trodelvy (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer: Dosing and administration questions"
description: "Dosing and administration questions on Trodelvy (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Dosing, Treatment combinations, Preparation, and Administration. Questions: What is the TRODELVY dose and treatment schedule? What is the maximum dose of TRODELVY? Who is eligible for TRODELVY plus pembrolizumab in metastatic TNBC? With TRODELVY, how long is pembrolizumab continued? 5 further questions follow. 9 questions quoted from 6 sources."
canonical: "https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/dosing-and-administration"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Trodelvy (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer: Dosing and administration questions

Manufacturer: Gilead Sciences, Inc.  
Prescribing information: [Trodelvy](https://www.gilead.com/-/media/files/pdfs/medicines/oncology/trodelvy/trodelvy_pi.pdf)

## Dosing

<a id="trodelvy-dosing-cycle"></a>

### What is the TRODELVY dose and treatment schedule?

> “The recommended dosage of TRODELVY as a single agent or in combination with pembrolizumab is 10 mg/kg intravenously on Days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity
>
> Do not administer TRODELVY at dosages greater than 10 mg/kg
> Administer TRODELVY as an intravenous infusion
> Do NOT substitute TRODELVY for or use with other drugs containing irinotecan or its active metabolite, SN-38
> 21-day cycles
>
> Observe patients during the infusion and for at least 30 minutes following the infusion for signs or symptoms of infusion-related reactions.”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/dosing-schedule#:~:text=The%20recommended%20dosage%20of%20TRODELVY,or%20symptoms%20of%20infusion%2Drelated%20reactions.)

<a id="trodelvy-maximum-dose"></a>

### What is the maximum dose of TRODELVY?

> “Do not administer TRODELVY at doses greater than 10 mg/kg.”

Source: [TRODELVY: Prescribing information, page 4, captured 2026-11-08](https://www.gilead.com/-/media/files/pdfs/medicines/oncology/trodelvy/trodelvy_pi.pdf#page=4)

<a id="trodelvy-dose-modifications"></a>

### How should the TRODELVY dose be modified for side effects?

> “Do not reescalate the TRODELVY dose after a dose reduction for adverse reactions has been made.”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/safety-profile#:~:text=Do%20not%20reescalate%20the%20TRODELVY,adverse%20reactions%20has%20been%20made.)

> “Table 1: Dosage Reduction Levels 
> Dose Reduction* 
> Dosage and Schedule 
> First  
> Reduce to 7.5 mg/kg  
> Second  
> Reduce to 5 mg/kg  
> *Permanently discontinue TRODELVY in patients unable to tolerate 5 mg/kg.”

Source: [TRODELVY: Prescribing information, page 4, captured 2026-11-08](https://www.gilead.com/-/media/files/pdfs/medicines/oncology/trodelvy/trodelvy_pi.pdf#page=4)

> “Dose modifications for adverse reactions<sup>1</sup>
> Adverse reactions
> Severity
> Dose modification
> Neutropenia
> Grade 3–4 neutropenia (absolute neutrophil count [ANC] <1000/mm<sup>3</sup>) or febrile neutropenia
> Withhold TRODELVY until ANC ≥1500/mm<sup>3</sup> for Day 1 dose or ANC ≥1000/mm<sup>3</sup> for Day 8 dose
> Administer G-CSF during treatment as clinically indicated
> Reduce by 1 dose level for each occurrence of febrile neutropenia or prolonged Grade 3–4 neutropenia, or permanently discontinue according to the dosage reduction levels information above
> Nausea/Vomiting/
> Diarrhea
> Grade 3–4 nausea, vomiting, or diarrhea that is not controlled with antiemetics or anti-diarrheal agents
> Withhold TRODELVY until resolved to ≤Grade 1
> Reduce by 1 dose level with each occurrence or permanently discontinue according to the dosage reduction levels above
> Infusion-Related Reaction
>
> Grade 1–3 infusion-related reactions
>
> Grade 4 infusion-related reactions
>
> Slow infusion rate or interrupt the infusion
> Permanently discontinue TRODELVY
> Other Toxicities
> Other Grade 3–4 toxicities of any duration despite optimal medical management
> Withhold TRODELVY until resolved to ≤Grade 1
> Reduce by 1 dose level with each occurrence or permanently discontinue according to the dosage reduction levels above”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/safety-profile#:~:text=Dose%20modifications%20for%20adverse,or%20permanently%20discontinue%20according%20to%20the%20dosage%20reduction%20levels%20above)

> “When administering TRODELVY in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, interrupt or discontinue one or both drugs of the combination or reduce the dose of TRODELVY to manage adverse reactions as appropriate. Refer to the Prescribing Information for pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for recommendations on dosage interruption or discontinuation due to adverse reactions.”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/safety-profile#:~:text=When%20administering%20TRODELVY%20in%20combination,discontinuation%20due%20to%20adverse%20reactions.)

Note: The dosage reduction levels appear as an image on the safety page and are quoted from the linked Prescribing Information.

## Treatment combinations

<a id="trodelvy-combination-selection"></a>

### Who is eligible for TRODELVY plus pembrolizumab in metastatic TNBC?

> “Select patients for treatment of unresectable locally advanced or metastatic TNBC with TRODELVY in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, based on the tumor expression of PD-L1 as confirmed by an FDA-authorized test.
>
> Information on FDA-authorized tests is available at https://www.fda.gov/companiondiagnostics”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/dosing-schedule#:~:text=Select%20patients%20for%20treatment%20of,tests%20is%20available%20at%20https%3A%2F%2Fwww.fda.gov%2Fcompaniondiagnostics)

> “In combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for the first-line treatment of unresectable locally advanced or mTNBC whose tumors express PD-L1 [Combined Positive Score (CPS ≥10)] as determined by an FDA-authorized test”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/important-safety-information#:~:text=In%20combination%20with%20pembrolizumab%20or,determined%20by%20an%20FDA%2Dauthorized%20test)

<a id="trodelvy-combination-duration"></a>

### With TRODELVY, how long is pembrolizumab continued?

> “When TRODELVY is administered in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, discontinue pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, after approximately 24 months.
>
> Refer to the Prescribing Information for pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for the recommended dosing information”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/dosing-schedule#:~:text=When%20TRODELVY%20is%20administered%20in,for%20the%20recommended%20dosing%20information)

## Preparation

<a id="trodelvy-vial-storage"></a>

### How should TRODELVY vials be stored?

> “Store vials in a refrigerator at 2 °C to 8 °C (36 °F to 46 °F) in the original carton to protect from light until time of reconstitution. Do not freeze.”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/reconstitution-and-administration#:~:text=Store%20vials%20in%20a%20refrigerator,of%20reconstitution.%20Do%20not%20freeze.)

<a id="trodelvy-reconstitution"></a>

### How is a TRODELVY vial reconstituted?

> “Using a sterile syringe, slowly inject 20 mL of 0.9% Sodium Chloride Injection, USP, into each 180 mg TRODELVY vial
> Each vial contains overfill to compensate for liquid loss during preparation and after reconstitution
> The total resulting volume delivers a concentration of 10 mg/mL
> Gently swirl vials and allow to dissolve for up to 15 minutes. Do not shake
> Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit
> The solution should be free of visible particulates, clear, and yellow
> Do not use the reconstituted solution if it is cloudy or discolored
> Use reconstituted TRODELVY immediately to prepare a diluted TRODELVY infusion solution”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/reconstitution-and-administration#:~:text=Using%20a%20sterile%20syringe%2C%20slowly,a%20diluted%20TRODELVY%20infusion%20solution)

This passage is in a collapsed section of the page; select: Reconstitution

Note: Covers vial reconstitution; dilution and administration steps are in the linked reconstitution guide.

## Administration

<a id="trodelvy-premedication"></a>

### What premedications are recommended before each TRODELVY infusion?

> “Prior to each dose of TRODELVY, premedication for prevention of infusion reactions and of chemotherapy-induced 
> nausea and vomiting (CINV) is recommended. 
> • 
> Premedicate with antipyretics, H1 and H2 blockers prior to infusion, and corticosteroids may be used for patients 
> who had prior infusion reactions.  
> • 
> Premedicate with a 2 or 3 drug combination regimen (e.g., dexamethasone with either a 5-HT3 receptor 
> antagonist or an NK1 receptor antagonist, as well as other drugs as indicated).”

Source: [TRODELVY: Prescribing information, page 4, captured 2026-11-08](https://www.gilead.com/-/media/files/pdfs/medicines/oncology/trodelvy/trodelvy_pi.pdf#page=4)

<a id="trodelvy-infusion-time"></a>

### How long does a TRODELVY infusion take?

> “First infusion: Administer over 3 hours. Observe patients during the infusion and for at least 30 minutes 
> following the initial dose, for signs or symptoms of infusion-related reactions
> • Second and subsequent infusions: Administer over 1 to 2 hours if prior infusions were tolerated. 
> Observe patients during the infusion and for at least 30 minutes after infusion”

Source: [TRODELVY: trodelvyreconstitution-dilution-and-admin-guideustrop1717.pdf, page 4, captured 2026-11-08](https://www.trodelvyhcp.com/-/media/affinity/trodelvyhcp/hcp/resource-pdf/trodelvyreconstitution-dilution-and-admin-guideustrop1717.pdf#page=4)

## Related pages
- [Medical information: Trodelvy (sacituzumab govitecan-hziy): Metastatic triple-negative breast cancer](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/drug-interactions)
- [Access and coverage](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/guidelines)
